Safety and Quality of Life of Various Artificial Pancreas Systems in Patients With Type 1 Diabetes Mellitus: A Systematic Review of Real-World Evidence

Author(s)

Kaushik P, Arya S, Singh N, Afaque A, Nanda S, Grover R, Syal K
Quantify Research, Sahibzada Ajit Singh Nagar (Mohali), PB, India

Presentation Documents

OBJECTIVES: Type 1 diabetes mellitus (T1DM) requires continuous glucose monitoring and intensive insulin therapy. Artificial pancreas (AP) may offer ideal treatment option improving quality of life (QoL) and minimizing safety risks. This systematic review assessed the real-world evidence on the safety and QoL of AP systems in the management of T1DM.

METHODS: A systematic review adhering to PRISMA guidelines was conducted in Embase® and PubMed® to identify literature published from January 2018 until May 2023. Real-world studies reporting safety and QoL of various AP systems for T1DM management were included.

RESULTS: A total of 2,020 records were retrieved from Embase® and PubMed®. After deduplication, 1,713 publications were reviewed by screening titles and abstracts, followed by full-text screening of 174 publications which finally led to the inclusion of 55 unique publications. Almost half (47.2%) of these were published in the year 2022. Highest proportion (20.6%) of the studies were conducted in the United States and retrospective observational study design was the most (43.6%) adopted amongst all study designs. Advanced hybrid closed loop (34.5%) and hybrid closed loop (29.1%) were the most evaluated AP systems in the included evidence. A total of 37 (74%) studies reported safety-related data, of which 48.6% reported adverse events (AEs)/complications and the remaining 51.4% reported absence of AEs. Severe hypoglycemia (50%) was the most frequently reported AE followed by diabetic ketoacidosis (33.3%). Twenty-two publications utilized surveys and questionnaires to collect the QoL data, of which all except one reported improvement in the QoL. The most frequently used QoL tools were psychosocial variables including Hypoglycemia Fear Survey (36.3%), and Problem Areas in Diabetes (18.1%).

CONCLUSIONS: Real-world evidence identified from our review indicated that the AP systems improved QoL, thereby reducing the burden of T1DM. However, there is a need for further evaluation of the safety aspects of the AP systems.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

PCR222

Topic

Clinical Outcomes, Medical Technologies, Patient-Centered Research, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Literature Review & Synthesis, Medical Devices, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×